Syros Pharmaceuticals Inc   (SYRS)
Other Ticker:  

Syros Pharmaceuticals Inc's Customers Performance


SYRS's Source of Revenues During the corresponding time, Syros Pharmaceuticals Inc revenue deteriorated by -3.32 % year on year, sequentially revenue grew by 32.79 %. While revenue at the Syros Pharmaceuticals Inc 's corporate clients

List of SYRS Customers

for the same period Syros Pharmaceuticals Inc revnue deteriorated by -3.32 % year on year, sequentially revenue grew by 32.79 %.

List of SYRS Customers

Syros Pharmaceuticals Inc's Comment on Sales, Marketing and Customers

  News about Syros Pharmaceuticals Inc Contracts

Syros Pharmaceuticals Reports Strong First Quarter 2024 Financial Results and Advances Tamibarotene for Frontline Treatment of Hematologic Malignancies


Breakthrough or Bustn Syros Pharmaceuticals Nears Milestone in HR-MDS Treatment Trial

In a significant development for the biopharmaceutical industry, Syros Pharmaceuticals has announced the successful completion of patient enrollment in the SELECT-MDS-1 Phase 3 clinical trial. The trial aims to evaluate the efficacy of tamibarotene in treating newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression. With the enrollment of 190 patients, this crucial initial cohort constitutes the necessary support for the primary endpoint analysis.Myelodysplastic syndromes (MDS) are a group of hematological malignancies characterized by ineffective production of blood cells, leading to a wide range of symptoms and medical complications. HR-MDS, in particular, poses...

Syros Pharmaceuticals Sets High 2024 Milestones for Tamibarotene Amid Financial Hurdles

Syros Pharmaceuticals, a prominent biopharmaceutical company headquartered in Cambridge, Massachusetts, has recently released its anticipated milestones for the year 2024. As a leader in the development of innovative treatments for hematologic malignancies, Syros Pharmaceuticals is seizing the new year with zeal and renewed commitment towards the advancement of its promising therapeutic solution, Tamibarotene.Despite experiencing a significant 54.86% year-on-year revenue decline, and a sequential revenue fall of 4.1%, the company remains steadfast in its mission. Bucking the waves of financial setbacks, Syros has set afoot on a path that could potentially revolutionize the standard of care for patients suffe...

Tamibarotene Shows Promising Results in Phase 2 Clinical Trial for Acute Myeloid Leukemia, Boosting Syros Pharmaceuticals Amid Revenue Decline

Syros Pharmaceuticals, a leading biopharmaceutical company focused on revolutionizing treatment options for hematologic malignancies, has recently released encouraging initial data from its ongoing SELECT-AML-1 Phase 2 clinical trial. The trial evaluates the efficacy of tamibarotene, an oral medication that acts as a selective retinoic acid receptor alpha (RAR) agonist, in combination with venetoclax and azacitidine for newly diagnosed, unfit patients with acute myeloid leukemia (AML).
The initial results from the trial have shown strong potential, serving as a ray of hope for patients suffering from this aggressive and life-threatening form of cancer. AML is a type of blood and bone marrow cancer ...

SYRS's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

Syros Pharmaceuticals Inc 175.50 8.80 -104.96 -
SUBTOTAL 0.00 0.00 0.00 -


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com